Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic LeukemiaJohn C. Byrd, Susan O’Brien, Richard R. Furman et al.|New England Journal of Medicine|2013Cited by 2.2k
Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell MalignanciesRanjana H. Advani, Nathan Fowler, Joseph J. Buggy et al.|Journal of Clinical Oncology|2012Cited by 1.1k
Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphomaWyndham H. Wilson, Louis M. Staudt, Arthur L. Shaffer et al.|Nature Medicine|2015Cited by 1.1k
JAK3 Inhibition Significantly Attenuates Psoriasiform Skin Inflammation in CD18 Mutant PL/J MiceBetty Chang, Daniel C. Bullard|The Journal of Immunology|2009Cited by 62